• T-DXd Continues Winning Streak in Metastatic, HER2-Positive Breast Cancer

    2 monthes ago - By MedPageToday

    SAN ANTONIO - Results from two randomized phase III trials supported the use of trastuzumab deruxtecan as a second- or third-line standard of care in patients with metastatic HER2-positive breast cancer...
    Read more ...

     

  • Neoadjuvant T-DXd Active in HER2-Low Breast Cancer

    Neoadjuvant T-DXd Active in HER2-Low Breast Cancer

    2 monthes ago - By MedPageToday

    SAN ANTONIO - Use of trastuzumab deruxtecan in patients with localized, hormone receptor -positive, HER2-low breast cancer demonstrated evidence of clinical activity in the neoadjuvant setting, according...
    Read more ...

     

  • Emerging Therapies in Metastatic Breast Cancer

    Emerging Therapies in Metastatic Breast Cancer

    2 monthes ago - By MedPageToday

    Promising findings from various clinical trials at the San Antonio Breast Cancer Symposium have the breast cancer research community buzzing about the future of treatment in metastatic disease. As we close out 2022, what...
    Read more ...